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Background: Sodium channel alpha 1 subunit gene,
SCN1A, is the gene encoding the neuronal voltage-gated
sodium channel  1 subunit (Nav1.1) and is mutated in
different forms of epilepsy. Mutations in this gene were
observed in more than 70% of patients with severe myo-
clonic epilepsy of infancy (SMEI) and were also found in
different types of infantile epileptic encephalopathy.
Objective: To search for disease-causing mutations in
SCN1A in patients with cryptogenic epileptic syndromes
(ie, syndromes with an unknown cause).
Design: Clinical characterization and molecular ge-
netic analysis of a cohort of patients.
Setting:University hospitals, rehabilitation centers, and
molecular biology laboratories.
Patients: Sixty unrelated patients with cryptogenic epi-
leptic syndromes.
MainOutcomeMeasures: Samples of DNAwere ana-
lyzed for mutations and for large heterozygous dele-
tions encompassing the SCN1A gene. A search for mi-
crodeletions in the SCN1A gene was also performed in
the subset of patients with SMEI/SMEI-borderland who
had negative results at the point mutation screening.
Results: No large deletions at the SCN1A locus were
found in any of the patients analyzed. In contrast, 13 dif-
ferent point mutations were identified in 12 patients: 10
with SMEI, 1 with generalized epilepsy with febrile sei-
zures plus, and 1 with cryptogenic focal epilepsy. An ad-
ditional search for SCN1A intragenic microdeletions in
the remaining patients with SMEI/SMEI-borderland and
no point mutations was also negative.
Conclusions:These results confirm the role of the SCN1A
gene in different types of epilepsy, including crypto-
genic epileptic syndromes. However, large deletions en-
compassing SCN1A were not common disease-causing
rearrangements in this group of epilepsies.
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S ODIUM CHANNEL ALPHA 1 SUB-unit gene (SCN1A) (MIM182389,GenBankAB093548)is the gene most commonlymutated in different forms of
epilepsy and it encodes the sodium chan-
nel1 subunit (Nav1.1).1Mutations in this
gene are observed inmore than 70%of pa-
tientswith severemyoclonic epilepsyof in-
fancy (SMEI),1-5 a syndrome with seizure
onset in the first year of life and typically
beginning with prolonged febrile hemi-
clonic or generalized tonic-clonic sei-
zures.2 Subsequently, other types of sei-
zuresoccur, suchasmyoclonic, partial, and
absenceseizures,whichare refractory toan-
tiepilepticdrug treatment.Psychomotorde-
velopment isnormaluntil seizureonset and
then progressively slows down, leading to
moderate to severe mental retardation.5
More than170mutations of SCN1A are as-
sociated with SMEI1,4 and SMEI border-
land (SMEB).4,6,7 Approximately 95% of
SCN1A mutations arise de novo, and the
remainder show familial segregation in
generalized epilepsy with febrile seizures
plus (GEFS).4,8 Mosaicism for SCN1A
mutations has also been reported in un-
affected parents of patients with SMEI or
SMEB.9-12 Besides SMEI, SMEB, and
GEFS, thephenotypicspectrumofSCN1A
also includes intractable childhood epi-
lepsy with generalized tonic-clonic sei-
zures.13 West syndrome is also associated
with SCN1A, although only 1 mutation in
1 case has been reported so far.14 Focal epi-
lepsy, such as temporal lobe epilepsy, pre-
senting occasionally within the GEFS
spectrum, was associated with an SCN1A
mutation as well.15,16 A novel SCN1Amu-
tation was also detected in a family with
members affected by simple febrile sei-
zures, with some of them later developing
temporal lobe epilepsy.17
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It was recently found that intragenic andwhole SCN1A
gene deletions also occur in a variable percentage (8%-
27%) of patients with SMEI without point mutations in
SCN1A.18-21 The overlapping yet heterogeneous clinical
features of the epilepsy syndromes associatedwith SCN1A
mutations recently led a group of researchers to search
for mutations in this gene in a large sample of unse-
lected patients with epileptic encephalopathies (includ-
ing SMEI) with onset primarily during the first year of
life.4 In that study, they identified mutations in patients
with cryptogenic generalized epilepsy (CGE) and cryp-
togenic focal epilepsy (CFE) and in a subgroup classi-
fied as having severe infantile multifocal epilepsy.
Based on these results, we decided to screen the SCN1A
gene for mutations and whole gene deletions in 60 pa-
tients with cryptogenic epileptic syndromes with onset
in the first 2 years of life to evaluate the prevalence of
SCN1A abnormalities in this heterogeneous group of pa-
tients. All the patients with SMEI and SMEB who had
negative results at the pointmutation screeningwere also
analyzed for the presence of intragenic heterozygous de-
letions in the SCN1A gene. The results of these screen-
ings are presented and discussed.
METHODS
PATIENTS
Sixty patients (59 from Italy and 1 from Spain), selected based
on the criteria detailed herein, were referred formolecular analy-
sis to the Laboratory of Molecular Biology at the E. Medea Sci-
entific Institute, Lecco, Italy. These patients were first seenwith
an epileptic syndrome of unknown cause, which started in the
first 2 years of life; this diagnosis was based on normal mag-
netic resonance imaging findings and negative results of meta-
bolic and cytogenetic investigations.
Each patient has been followed up for a variable period (2-28
years) since the onset of the epileptic seizures. Clinical datawere
obtained from all the patients, and particular attentionwas given
to family history of seizure disorders; seizure onset, type, fre-
quency, and precipitating factors; drug response; and evolution
of electroclinicaldata. Severalpolygraphic-polysomnographic elec-
troencephalogramswere recorded. The patients enrolled in this
study could, thus, be classified into 6 different subgroups ac-
cording to the International League Against Epilepsy classifica-
tionof epileptic syndromes22 and the International LeagueAgainst
Epilepsy proposed diagnostic scheme for epilepsies23: SMEI
(n=14), SMEB (n=6), GEFS (n=12), West syndrome (n=7),
CFEandmultifocal epilepsies (n=8), andCGE(n=13). The term
SMEB was used for cases of SMEI without several key features
of SMEI.24 All the patients withWest syndrome enrolled in this
study were negative for mutations in the genes known for this
disease (aristaless-related homeobox [MIM 300382, GenBank
NM_139058] and cyclin-dependent kinase-like 5 [MIM300203,
GenBankNM_003159]). The CGE subgroup comprises 4 cases
of Lennox-Gastaut syndrome. The ethics committee of the E.
Medea Scientific Institute approved the study. Informed con-
sent was obtained from the parents of children and from adults
of normal intellect.
MOLECULAR ANALYSIS
Molecular analysis was performed on genomic DNA extracted
from blood using standard procedures. All 26 exons of SCN1A
were amplified by polymerase chain reaction (PCR) using flank-
ing intronic primers and standard PCR conditions. The PCR
fragments were sequenced using a kit (BigDye Terminator Se-
quencing Kit; Applied Biosystems, Foster City, California) and
were run on a genetic analyzer (ABI 3130 XL; Applied Biosys-
tems). The SCN1Amutation nomenclature is based on RefSeq
AB093548.1 (considering the A of the ATG as nt 1) according
to the recommendations of the Human Genome Variation So-
ciety. The appropriate PCR fragment fromparents’ DNA (where
available) was sequenced in all cases in which an SCN1A mu-
tation was detected to distinguish between de novo and famil-
ial variants. All the reported nucleotide changes were checked
in a panel of 250 control subjects. Quantitative PCR was per-
formed using probes designed on intron 3 and exons 8 and 26
of the SCN1A gene. The reactions were run on a detection sys-
tem (ABI 7900HT Sequence Detection System; Applied Bio-
systems). Multiplex ligation-dependent probe amplification
analysis was performed using a kit (SALSA MLPA P137 Kit;
MRC-Holland, Amsterdam, theNetherlands). Possible changes
in exonic splicing enhancers were assessed using the exonic
splicing enhancer finder algorithm (accessible at http://rulai
.cshl.edu/tools/ESE).
RESULTS
Of the 60 patients analyzed, 12 were found to carry mu-
tations in SCN1A: 10 with SMEI, 1 with GEFS, and 1
with CFE. No mutations were found in the remaining
epilepsy subgroups. The clinical features of patients with
mutations are summarized in Table 1 and described in
the following subsections, grouped by the type of epi-
lepsy syndrome.
SEVERE MYOCLONIC EPILEPSY OF INFANCY
All patients with mutations were born after an unevent-
ful pregnancy and delivery. Epilepsy started at 3 to 8
months of life in all patients with febrile (n=8) or afe-
brile (n=2) generalized (n=5) or hemiclonic (n=5) sei-
zures changing sides. Prolonged seizures or status epi-
lepticus was reported in all the patients except 3. Seven
patients started experiencing segmental or massive my-
oclonus jerks after 12 months of age; 4 developed par-
tial seizures and 5 experienced atypical absence sei-
zures; 1 patient had tonic seizures. At the neurologic
examination, 4 patients developed ataxia. Five patients
had severemental retardation, while 4 showed onlymild
cognitive deficits. Each patientwas treatedwithmore than
3 antiepileptic drugs without achieving complete sei-
zure control.
CRYPTOGENIC FOCAL EPILEPSY
One patient had a family history of unspecified epilepsy
in amaternal uncle, although both parents were healthy.
The delivery was complicated, and the patient has had
mild psychomotor retardation since the first year of life,
with lateralized (right) neurologic signs and a left ptosis
observed at age 10 months. Epilepsy started at age 3
months with generalized tonic-clonic seizures. Hemi-
clonic seizures involving only the left side subsequently
occurred, sometimes followed by febrile and afebrile con-
vulsive status epilepticus. This patient is now severely
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mentally retarded. Electroencephalograms revealed slowed
background activity and bursts of epileptiform abnor-
malities bilaterally over the frontal areas.
GENERALIZED EPILEPSY
WITH FEBRILE SEIZURES PLUS
The family history for this patient was unavailable. The
patient’s parents agreed to donate blood for genetic analy-
sis but refused to be clinically evaluated. The patient was
born after an uneventful pregnancy and delivery. Psy-
chomotor development was normal. Epilepsy started in
the first year of life with febrile generalized tonic-clonic
seizures. Generalized afebrile tonic-clonic seizures ap-
peared at age 3 years. He has never experienced pro-
longed seizures or status epilepticus. The patient is now
6 years old, and the seizures are well controlled with so-
dium valproate therapy. His intelligence and neurologic
examination results are normal.
MOLECULAR ANALYSIS
Mutation screeningofSCN1Aperformedbydirect sequenc-
ing of all exons led to the identification of 13mutations in
12 patients (Table2). Two truncatingmutations in exon
1 (p.Y65X) and exon 22 (p.W1434X) and 8missensemu-
tations distributed in exon 2 (p.R118S), exon 8 (p.D366E
and p.R377Q), exon 18 (p.L1207P), exon 21 (p.V1335M
and p.V1358S), exon 23 (p.Y1462C), and exon 26
(p.R1928G) were found. Mutations p.L1207P and
p.R1928G were present in the same patient (Table 2).
Frameshiftmutations due to a single base deletion in exon
19 (c.3774delA) or a 4–base pair deletion in exon 26
(c.5536_5539delAAAC) were also identified in 2 pa-
tients. The 2 deletions cause premature stop codon 63 and
10 base pairs downstream (p.L1296fs and p.K1846fs), re-
spectively.Asingle splicemutationaffecting thedonor splice
site of exon 8 (c.11701 G→A) was identified in 1 pa-
tient. No cell line from the patient was available to check
themutation effect ongene transcription; however, thebase
change most likely leads to either exon skipping or use of
a cryptic splice donor site. All themutations identified are
novel except for c.5536_5539delAAAC, which has al-
ready been reported.1,3,4,14,25 None of the novel mutations
were present in a panel of 250 controls. Themutations are
scattered throughout the Nav1.1 subunit protein, with the
S5-S6 segments (the pore-forming regions) of 2 domains,
DI andDIII, being themore frequent targets (Table 2).Most
of the mutations found, which could be tested for segre-
gationwithin the families (8 of 9), turnedout to bedenovo.
In addition to the pointmutation screening, wewanted to
exclude the presence of large heterozygous deletions en-
compassing the entire SCN1A gene in all point mutation–
negative patients. Quantitative PCR was, thus, performed
by using probes specific for intron 3 and exons 8 and 26
of the SCN1A gene. No large heterozygous SCN1A dele-
tions could be found in any of the patients tested. The
SCN1A intragenic microdeletions were also excluded by
using the multiplex ligation-dependent probe amplifica-
tion technique only in patients with SMEI/SMEBwho had
negative results at point mutation screening.
Table 1. Clinical and Electroclinical Features of Patients With SCN1A Mutations
Feature
Patient No.
1 2 3 4 5 6 7 8 9 10 11 12
Age at diagnosis, y 15 3 28 29 15 12 9 5 2 2 17 7
Epileptic syndrome SMEI SMEI SMEI CFE SMEI SMEI SMEI SMEI GEFS SMEI SMEI SMEI
Family history  − −  −  − − NA − − −
Seizures
Age at onset, mo 5 5 4 3 5 5 12 8 12 6 6 4
Type H GTC GTC GTC GTC H H H GTC GTC GTC H
Febrile      −  −    
Other type GTC ABS ABS,
tonic,
and
partial
Ha and
partial
− ABS
and H
Partial Partial − − ABS Partial
and
ABS
Frequency Daily Monthly Monthly Weekly NA Weekly Weekly Weekly Yearly Monthly Monthly Weekly
Status epilepticus     − − NA NA −  NA 
Myoclonus  −   −    − −  
Treatment Ref Ref Ref Ref Ref Ref Ref Ref Resp Ref Ref Ref
Neurologic examination NAD NAD Ataxia Ataxia Bab NAD Ataxia Ataxia NAD NAD NAD Ataxia
MR S Ml S S S M S M None M S M
MRI N N N N N N N N N N N N
EEG background in
childhood
N NA Sl Sl Sl Sl N Sl N N NA Sl
Photoparoxysmal
response
  − − −  − − − − NA 
Abbreviations: ABS, absence seizures; Bab, Babinski; CFE, cryptogenic focal epilepsy; EEG, electroencephalographic; GEFS, generalized epilepsy with febrile
seizures plus; GTC, generalized tonic-clonic; H, hemiclonic; M, moderate; Ml, mild; MR, mental retardation; MRI, magnetic resonance imaging; N, normal;
NA, not available; NAD, nonabnormal data; ref, refractory; resp, responsive; S, severe; Sl, slowly; SMEI, severe myoclonic epilepsy of infancy;, present; −, absent.
aAlways on the same side (see the “Results” section).
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COMMENT
Sixty patients with cryptogenic epileptic syndromes char-
acterized by seizure onset in the first 2 years of life were
tested for point mutations and whole gene deletions in
SCN1A. No large deletions including the SCN1A genewere
found in any patients, indicating that these rearrange-
ments are not frequently associated with cryptogenic epi-
leptic syndromes.However,13SCN1Apointmutationswere
detected in 12 patients. Most of these patients have SMEI
(10 of 12), with the remaining having GEFS and CFE.
SEVERE MYOCLONIC EPILEPSY OF INFANCY
The large percentage of SMEI in patientswith SCN1Amu-
tations was expected based on the reported data.1,4 In the
present study, 10 (71%) of 14 patients with SMEI ana-
lyzed showed SCN1Amutations, and this is in line with
the results obtained in the most recently reported large
patient sample screenings.1,4 One patient with SMEI car-
ried 2 heterozygous mutations in exons 18 and 26 of
SCN1A. Both changes affect evolutionary conserved resi-
dues and fall within gene regions representing frequent
targets of mutations. However, we cannot exclude that
at least 1 of the changes represents a rare variant. These
data, together with the results of the deletion screening,
indicate that SCN1Amutation detection in patients with
SMEI is still lower than 100%. This reinforces the idea
that themolecular genetic basis of SMEI is not fully known
yet, as was previously hypothesized.1
GENERALIZED EPILEPSY
WITH FEBRILE SEIZURES PLUS
We observed an SCN1A mutation in 1 GEFS patient
(patient 9) of the 12 analyzed (8%). This percentage is
consistent with the reported frequency of SCN1Amuta-
tions in families with GEFS (5%-10%).1 Other genes
known to be involved in this type of epilepsy, such as
SCN1B, SCN2A, and GABRG2, still need to be screened
in this sample.
CRYPTOGENIC FOCAL EPILEPSY
Unlike in the results of a recent study,4 only 1 of 8 pa-
tients with CFE in our study had an SCN1A mutation
(12.5% vs 22%). The only mutation found was the
c.5536_5539delAAAC deletion, which has been reported
so far in 4 other patients with a different clinical diagno-
sis. The patient describedherein is classified as havingCFE
owing to the presence of focal electroencephalographic ab-
normalities, hemiclonic seizures occurring always on the
same side, and lateralized neurologic deficits. Three pa-
tients already describedwith thismutation had SMEI,3,14,25
and a fourth was defined as having SMEB without gener-
alized spikewaves.4 The identificationbydifferent research-
ers of the samemutation in apparentlydifferent clinical phe-
notypesmight be due to either a blurred clinical distinction
between these epileptic syndromes or other genetic or en-
vironmental factors playing a role in the expression of the
epilepsy phenotype. This ideawould be consistentwith the
marked variability widely reported in patients with SMEI
and related parents carrying the same mutation and with
the hypothesis of a polygenic origin of SMEI, as previ-
ously suggested.1 Functional data on the mutant protein
will contribute to addressing this issue.
The negative results obtained in the other subgroups
of patients, such as the West and Lennox-Gastaut syn-
dromes subgroups and theCGE subgroup, are only partly
unexpected. Indeed, the previous identification of only
1 SCN1A mutant case in the West and Lennox-Gastaut
syndromes,4,14 together with the present negative re-
sults, indicates that SCN1A is a rare cause of disease in
these syndromes. These findings also suggest that an
SCN1Amutation search may not be necessary in routine
diagnostic practice for these forms of epilepsy, but rather
that it should be considered for research purposes.
Overall, the negative results at the SCN1A mutation
screening in the CGE subgroup, compared with the re-
markable percentage (24%) of patients with SCN1Amu-
tations in the CGE subgroup analyzed byHarkin and col-
leagues,4 might be explained by the likely clinical
heterogeneity between the 2 CGE subgroups tested. The
Table 2. SCN1A Mutations
Patient No./
Phenotype Nucleotide Change
Amino Acid
Change
Exon/
Intron
ESE
Change
SCN1A
Domain Inheritance
2/SMEI c.195TA p.Y65X 1 NA NH2 ter De novo
1/SMEI c.354GC p.R118S 2 Yes NH2 ter De novo
10/SMEI c.1098TA p.D366E 8 Yes DI-S5-S6 De novo
9/GEFS c.1130GA p.R377Q 8 Yes DI-S5-S6 Maternal
11/SMEI c.11701 GA NA IVS8 NA DI-S5-S6 De novo
3/SMEI c.3774delA p.L1269fs 19 NA DIII-S2 De novo
5/SMEI c.4003GA p.V1335M 21 Yes DIII-S4-S5 ND
8/SMEI c.4073GC p.W1358S 21 No DIII-S5 De novo
7/SMEI c.4301GA p.W1434X 22 NA DIII-S4-S5 De novo
6/SMEI c.4385AG p.Y1462C 23 No DIII-S6 ND
4/CFE c.5536_5539delAAAC1,3,4,14,25 p.K1846fs 26 NA COOH ter De novo
12/SMEI c.5782CG p.R1928G 26 Yes COOH ter ND
c.3620TC p.L1207P 18 No DII-DIII linker
Abbreviations: CFE, cryptogenic focal epilepsy; COOH ter, COOH terminus; ESE, exonic splicing enhancer; GEFS, generalized epilepsy with febrile seizures
plus; NA, not available; ND, not determined; NH2 ter, NH2 terminus; SMEI, severe myoclonic epilepsy of infancy.
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same reason may explain the different percentages of
SCN1A mutants in the CFE subgroups as well. Such
heterogeneity may originate from the different types of
epilepsy examined in the 2 studies: the severe epileptic
encephalopathies with onset in the first year of life in the
first study4 vs the cryptogenic epileptic syndromes with
onset in the first 2 years of life tested herein. Based on
this, the present data seem to indicate that the earlier and
more severe the clinical and electroencephalographic pre-
sentations are, the higher the probability of finding mu-
tations in SCN1A is. However, additional experimental
evidence is required to confirm this hypothesis.
SCN1A MUTATIONS
Twelve of the 13 SCN1Amutations identified in this study
are novel, thus supporting the concept of mutational
heterogeneity that is typical of SCN1A. Most of the mu-
tations found (8 of 9 tested)were de novo, consistentwith
the data in the literature.4
Seven of the 13 mutations found, including mis-
sense, nonsense, and deletions, fall within the S5-S6 seg-
ments of the DI and DIII domains of the Nav1.1 subunit.
Whereas the pathogenic effect of a truncating mutation
is clear, the postulated pathogenicity of missense muta-
tions fallingwithin these segments needs functional dem-
onstration. These segments represent the pore-forming
region of the channel subunit; therefore, any change af-
fecting the properties of the constituting residues, such
as the charge or the steric hindrance (as in mutations
p.V1335M and p.Y1462C) or both (as in mutations
p.R377Q and p.W1358S), is supposed to variably affect
channel activity. In addition, all the identified missense
mutations change an evolutionary conserved amino acid
residue, and all but 3 (p.W1358S, p.Y1462C, and
p.L1207P) determine a putative exonic splicing en-
hancer sequence change. These sites are well-known to
play a role in constitutive and alternative splicing events.26
In conclusion, this study represents the second sys-
tematic study of SCN1A mutations in cryptogenic epi-
lepsies and confirms the findings of the first study4 con-
ducted on a larger sample of patients, although with
different results for some types of epilepsy. The results
of these 2 studies are supported and completed by the
previous findings of SCN1Amutations in a condition pre-
viously considered to be symptomatic, such as the al-
leged vaccine encephalopathies (mutations found in 11
of 14 patients)27 or in adult cases with refractory epi-
lepsy and normal magnetic resonance imaging findings
with onset in infancy (10 of 14 patients).5
These data altogether extend the spectrumof the clini-
cal phenotypes associated with SCN1Amutations to in-
clude SMEI and other epileptic encephalopathies and dif-
ferent types of cryptogenic epilepsieswith clear diagnostic
implications. All these studies are actually single pieces
of an apparently big puzzle representing the wide and
heterogeneous spectrum of pathologicmanifestations as-
sociated with Nav1.1 subunit dysfunctions.
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